HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Aridis Pharmaceuticals (OTC:ARDS) but has lowered the price target from $10 to $2.
October 20, 2023 | 5:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aridis Pharmaceuticals' price target has been lowered from $10 to $2 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Aridis Pharmaceuticals by such a significant amount indicates a potential decrease in the stock's value. However, the maintained 'Buy' rating suggests that the analyst still sees potential in the company. This could lead to short-term uncertainty and potential downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100